Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection
Primary Purpose
Prehypertension, Hypertension Stage 1
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Placebo
Djulis-Buckwheat
Buckwheat
Sponsored by
About this trial
This is an interventional prevention trial for Prehypertension
Eligibility Criteria
Inclusion Criteria:
- Systolic blood pressure 121-159 mmHg or Diastolic blood pressure 81-99 mmHg
- Age: 30-65
Exclusion Criteria:
- Have diagnosed and documented critical illness(NHI specification)
- Had emergency record or admission note in the past three months
- Not be pregnant or breast-feeding a child
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Experimental
Arm Label
Djulis-Buckwheat & Placebo
Buckwheat & Placebo
Djulis-Buckwheat & Buckwheat
Arm Description
Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
Outcomes
Primary Outcome Measures
Change of blood pressure
Secondary Outcome Measures
Full Information
NCT ID
NCT02825901
First Posted
June 14, 2016
Last Updated
July 6, 2016
Sponsor
Taipei Medical University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02825901
Brief Title
Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection
Official Title
Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection
Study Type
Interventional
2. Study Status
Record Verification Date
June 2016
Overall Recruitment Status
Unknown status
Study Start Date
July 2016 (undefined)
Primary Completion Date
January 2017 (Anticipated)
Study Completion Date
March 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taipei Medical University Hospital
4. Oversight
5. Study Description
Brief Summary
The purpose of the trial is to evaluate the effect of Djulis-Buckwheat drink on cardiovascular protection after ingesting for 8 weeks. In addition, the correlation between the supplement and the cardiovascular disease-related gene expression is evaluated. The results will be used for the application of functional products for cardiovascular protection.
Ninety subjects (age 30~65) with Prehypertension or Hypertension stage 1 will be included and randomly allocated into 3 groups: Placebo, Djulis-Buckwheat and Buckwheat. The subjects will take sample (100 ml/day) for 8 weeks. Blood pressure will be measured on week 0, 1, 2, 4, 6 and 8. The blood biochemical parameters and gene expression analysis will be examined on week 2, 4, 6, 8 and 10 (the follow up).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prehypertension, Hypertension Stage 1
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
90 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Djulis-Buckwheat & Placebo
Arm Type
Active Comparator
Arm Description
Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
Arm Title
Buckwheat & Placebo
Arm Type
Active Comparator
Arm Description
Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
Arm Title
Djulis-Buckwheat & Buckwheat
Arm Type
Experimental
Arm Description
Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Djulis-Buckwheat
Intervention Type
Dietary Supplement
Intervention Name(s)
Buckwheat
Primary Outcome Measure Information:
Title
Change of blood pressure
Time Frame
Baseline, 1, 2, 4, 6, and 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Systolic blood pressure 121-159 mmHg or Diastolic blood pressure 81-99 mmHg
Age: 30-65
Exclusion Criteria:
Have diagnosed and documented critical illness(NHI specification)
Had emergency record or admission note in the past three months
Not be pregnant or breast-feeding a child
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shih Chun-Ming, PhD
Phone
886-2-27372181
Ext
8603
Email
cmshih53@tmu.edu.tw
12. IPD Sharing Statement
Learn more about this trial
Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection
We'll reach out to this number within 24 hrs